Tumor-associated antigen-bound trans-cyclooctene-modified monoclonal antibody (No widely recognized abbreviation exists for this generic construct; abbreviations like "TCO-mAb" or "TCO-antibody" are sometimes used in context[3][4], but these are not target-specific.)

A tumor-associated antigen-bound trans-cyclooctene-modified monoclonal antibody is an engineered antibody that selectively binds a cancer cell antigen and is chemically linked to trans-cyclooctene groups. This modification enables rapid, selective chemical reactions with tetrazine-functionalized agents, facilitating highly specific tumor imaging or localized drug delivery via a bioorthogonal "click" reaction. The approach overcomes slow pharmacokinetics and background noise inherent to unmodified antibodies, enhances imaging contrast, and enables triggerable drug release in antibody-drug conjugate systems[1][2][3][4][5]. The specific biological activity and disease role are determined by the choice of the tumor-associated antigen that the antibody recognizes.

Other names

TCO-modified antibodyTumor-targeted trans-cyclooctene antibodyTCO-mAb

Antibody binds to tumor-associated antigen on cancer cells. TCO on antibody reacts rapidly and selectively with tetrazine-modified imaging agents or drugs (via inverse electron-demand Diels-Alder reaction), enabling visualization or drug delivery to tumors[1][3][4].